Juvenile myoclonic epilepsy with recurrent myoclonic status: Efficacy of valproate;Épilepsie myoclonique juvénile avec états demal myocloniques récurrents : eefficacit́e du valproate

Therapie

Volumn 64, Issue 5, 2009, Pages 321-323

  Crespel, Arielle ^a   Velizarova, Reana ^a   Genton, Pierre ^b   Gélisse, Philippe ^a  

^a Unité Médico Chirurgicale de l'Ipilepsie   (France)

^b CENTRE SAINT PAUL   (France)

Author keywords

Idiopathic generalized epilepsy; Juvenile myoclonic epilepsy; Lamotrigine; Levetiracetam; Myoclonic status epilepticus; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; CLONAZEPAM; ETIRACETAM; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE; DRUG DERIVATIVE; PIRACETAM; TRIAZINE DERIVATIVE;

ADULT; ALOPECIA; CASE REPORT; DISEASE FREE INTERVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPTIC STATE; EVENING DOSAGE; HUMAN; JUVENILE; MONOTHERAPY; MORNING DOSAGE; MYOCLONUS EPILEPSY; PRIORITY JOURNAL; RECURRENT DISEASE; SEIZURE; SHORT SURVEY; SOMNOLENCE; ARTICLE; DRUG COMBINATION; MALE; MYOCLONUS;

ADULT; ANTICONVULSANTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MYOCLONIC EPILEPSY, JUVENILE; MYOCLONUS; PIRACETAM; RECURRENCE; TRIAZINES; VALPROIC ACID;

EID: 73649115302     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2009033     Document Type: Article

References (15)

1. Thomas P, Genton P, Gélisse P, et al. Épilepsie myoclonique juvénile. In: Roger J, Bureau M, Dravet Ch et al., editors. Les syndromes épileptiques de l'enfant et de l'adolescent, 4e éd. Montrouge: John Libbey Eurotext, 2005: 367-388
2. Gélisse Ph, Malafosse A, Genton P, et al. Aspects génétiques de l'épilepsie myoclonique juvénile. Epilepsies 2001; 13: 97-102 (Pubitemid 32607080)
3. Obeid T, Panayiotopoulos CP. Juvenile myoclonic epilepsy: a study in Saudi Arabia. Epilepsia 1988; 29: 280-282
4. Gélisse P, Genton P, Raybaud C, et al. Structural brain lesions do not influence the prognosis of juvenile myoclonic epilepsy. Acta Neurol Scand 2000; 102: 188-191
5. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1016-1026 (Pubitemid 46436125)
6. De Toffol B, Autret A. Treatment of juvenile myoclonic epilepsy with lowdose sodium valproate. Rev Neurol (Paris) 1996; 152: 708-710
7. Gélisse P, Crespel A, Genton P. Les médicaments antiépileptiques. Therapie 2008; 63: 425-451
8. Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000; 55: 1758
9. Crespel A, Genton P, Berramdane M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005; 65: 762-765
10. Biton V, Bourgeois BF, YTC/YTCE Study Investigators.Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol 2005; 62: 1705-1708
11. Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004; 6: 267-270
12. Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70: 607-616
13. Specchio LM, Gambardella A, Giallonardo AT, et al. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res 2006; 71: 32-39
14. Gélisse P, Genton P, Thomas P, et al. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry 2001; 70: 240-243
15. Nicolson A, Appleton RE, Chadwick DW, et al. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004; 75: 75-79